1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1. Drivers
4.1.1. Lower manufacturing costs
4.1.2. Increasing investments in research and development
4.1.3. Increased focus on core competence
4.1.4. Shorter time-to-market
4.2. Restraints
4.2.1. Stringent regulatory requirements
4.2.2. Increasing logistics costs and lead time
4.3. Opportunities
4.3.1. High demand for next-generation biological therapies
4.3.2. Final dosage form manufacturing
4.4. Constraints
4.4.1. Lack of information integration and manufacturing standardization
4.4.2. Lack of in-house laboratory capacity
4.4.3. Increasing complexity of clinical trials
5. Europe Pharmaceutical Contract Manufacturing Market– By Type
5.1. Introduction
5.2. Sterile
5.3. Non-Sterile
6. Europe Pharmaceutical Contract Manufacturing Market– By Product
6.1. Introduction
6.2. Finished Dosage Formulations
6.2.1. Solid dose formulation
6.2.2. Liquid dose formulation/Semi-solid formulation
6.2.3. Injectable dose formulation
6.3. Active Pharmaceutical Ingredients
6.4. Otc medicines and nutritional products
6.5. Advanced drug delivery products
6.6. Secondary packaging market
6.7. Others
7. Europe Pharmaceutical Contract Manufacturing Market– By Industry
7.1. Introduction
7.2. Pharmaceutical
7.3. Biopharmaceutical
8. Europe Pharmaceutical Contract Manufacturing Market– By Technology
8.1. Dosage formulation technologies
8.1.1. Lipid martiparticulate technology
8.1.2. Abuse-detergent formulation technology
8.1.3. Force control agent technology
8.1.4. Dry powder inhalation technology
8.1.5. Fluidized bed coating technology
8.1.6. Form Eze technology
8.1.7. High-potency drug formulation technology
8.2. Dosage forms by route of administration
8.2.1. Topical
8.2.2. Oral
8.2.3. Rectal
8.2.4. Parenteral
8.2.5. Optic
8.2.6. Vaginal
8.2.7. Inhaled
8.2.8. Ophthalmic
9. Europe Pharmaceutical Contract Manufacturing Market– By Geography
9.1. Introduction
9.2. Europe
9.2.1. U.K.
9.2.2. Germany
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Russia
9.2.7. Others
10. Europe Pharmaceutical Contract Manufacturing Market- Company Profiles
10.1. Recipharm AB
10.2. Catalent, Inc.
10.3. Haupt Pharma
10.4. Jubliant life sciences Ltd
10.5.Vetter pharma-fertigung GMBH & CO.KG
10.6. Aenova
10.7. Pfizer Centresource
10.8. Baxter biopharma solutions
10.9.Famar
11. Europe Pharmaceutical Contract Manufacturing Market- Competitive Landscape
11.1. Market Share Analysis
11.2. Strategies Adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
12. Market Insights
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
13. Appendix
13.1. List of tables
13.2. List of figures
